Patents by Inventor Yusuke Shintani
Yusuke Shintani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092784Abstract: A condensed heterocyclic compound has a sepiapterin reductase inhibitory action and is particularly useful for treatment of a pain. The condensed heterocyclic compound represented by Formula (I) below (R1 represents a hydrocarbon group or the like; R2 and R3 represent a hydrogen atom or the like; R4, X, and Y represent defined substituents), a tautomer or a pharmaceutically acceptable salt of the compound, or a solvate of any of these.Type: ApplicationFiled: April 13, 2021Publication date: March 21, 2024Applicants: NISSAN CHEMICAL CORPORATION, SHIONOGI & CO., LTD.Inventors: Masahiro KAMAURA, Yusuke INABA, Yusuke SHINTANI, Yuki KUWANO, Moemi NAKAO, Hiroshi NAGAI, Noriyuki KUROSE, Kenji TAKAYA, Mado NAKAJIMA
-
Publication number: 20240030833Abstract: An inverter including two switching elements of an inverter circuit connected in series to each other, drivers configured to respectively drive switching elements, and protection circuits each configured to transmit an output signal of the driver to each of the switching elements via a first resistor element. The protection circuit includes a second resistor element arranged to be electrically connectable in parallel to a first resistor element and a switch configured to switch between a first state in which electrical parallel connection of the second resistor element to the first resistor element is enabled and a second state in which the connection is cancelled. The protection circuit is configured to determine whether a short-circuit current has been generated in a first pattern or a second pattern and switch the switch to the first state in a case of determining that the short-circuit current of the second pattern has been generated.Type: ApplicationFiled: July 10, 2023Publication date: January 25, 2024Applicant: KABUSHIKI KAISHA TOYOTA JIDOSHOKKIInventor: Yusuke SHINTANI
-
Publication number: 20230181587Abstract: This invention relates to an antidepressant/anxiolytic drug comprising a compound represented by the following formula (I) or (II), wherein R1 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; R2 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.Type: ApplicationFiled: May 7, 2021Publication date: June 15, 2023Applicants: KAGOSHIMA UNIVERSITY, OSAKA UNIVERSITYInventors: Takashi KURIHARA, Ichiro TAKASAKI, Hitoshi HASHIMOTO, Atsuko HAYATA, Yusuke SHINTANI
-
Publication number: 20160340322Abstract: Disclosed is a novel triazinone compound with an inhibitory activity on a T-type voltage-dependent calcium channel, and is specifically useful for prevention or treatment of pain, chronic kidney disease and atrial fibrillation. A novel triazinone compound of Formula (I), wherein each substituent in the formula is defined in detail in the description, R4 means a hydrogen atom, or a C1-6 alkoxy group, etc., L1 and L2 each independently mean a single bond, or NR2, etc., L3 means a C1-6 alkylene group, etc., A means a C6-14 aryl group or a 5 to 10-membered heteroaryl group which may be substituted, B means a C3-11 cycloalkylene group, etc., D means a C6-14 aryl amino group or a 5 to 10-membered heteroaryl group which may be substituted, etc., a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, or the pharmaceutically acceptable salt.Type: ApplicationFiled: December 17, 2014Publication date: November 24, 2016Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Michiaki ADACHI, Masataka MINAMI, Jun EGI, Yuichi HIRAI, Toshimasa IWAMOTO, Yusuke SHINTANI, Takuya OKADA, Daiki TAKAHASHI
-
Publication number: 20160237071Abstract: A novel compound that has an excellent T-type calcium channel inhibitory activity and is specifically useful for prevention or treatment of pain, chronic kidney disease and atrial fibrillation. The novel triazinone compound of Formula (I): where each substituent in the formula is defined in detail in the description, and R1 could be a hydrogen atom, or a C1-6 alkyl group, etc., E could be a 7 to 14-membered non-aromatic fused heterocyclic group, L3 could be a C1-6 alkylene group, etc., D could be a C6-14 aryl group or a 5 to 10-membered heteroaryl group each of which is optionally substituted, etc., a tautomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof.Type: ApplicationFiled: October 2, 2014Publication date: August 18, 2016Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Masatoshi NIWA, Yusuke INABA, Toshimasa IWAMOTO, Yusuke SHINTANI, Hiroshi NAGAI, Jun EGI, Michiaki ADACHI, Yuichi HIRAI
-
Patent number: 9403798Abstract: There is provided a novel triazinone compound that has an excellent T-type voltage-dependent calcium channel inhibitory activity and is specifically useful for treatment of pain. A compound of Formula (I), a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof: where each substituent is defined in detail in the description or claims, for example R1 is H or C1-6 alkoxy, etc., each of L1 and L2 is independently a single bond or NR2, etc., L3 is C1-6 alkylene, etc., A is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc., B is C3-11 cycloalkylene, etc., D is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc.Type: GrantFiled: March 29, 2013Date of Patent: August 2, 2016Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Noriko Saito, Jun Egi, Hiroshi Nagai, Megumi Ueno, Yusuke Shintani, Yusuke Inaba, Michiaki Adachi, Yuichi Hirai, Takeshi Kawazu, Koichi Yasutake, Daiki Takahashi
-
Publication number: 20150065705Abstract: There is provided a novel triazinone compound that has an excellent T-type voltage-dependent calcium channel inhibitory activity and is specifically useful for treatment of pain. A compound of Formula (I), a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof: where each substituent is defined in detail in the description or claims, for example R1 is H or C1-6 alkoxy, etc., each of L1 and L2 is independently a single bond or NR2, etc., L3 is C1-6 alkylene, etc., A is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc., B is C3-11 cycloalkylene, etc., D is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc.Type: ApplicationFiled: March 29, 2013Publication date: March 5, 2015Inventors: Noriko Saito, Jun Egi, Hiroshi Nagai, Megumi Ueno, Yusuke Shintani, Yusuke Inaba, Michiaki Adachi, Yuichi Hirai, Takeshi Kawazu, Koichi Yasutake, Daiki Takahashi
-
Patent number: 8440666Abstract: Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.Type: GrantFiled: October 30, 2008Date of Patent: May 14, 2013Assignee: Nissan Chemical Industries, Ltd.Inventors: Yukihiro Shigeta, Yutaka Hirokawa, Hiroshi Nagai, Kei Nagae, Tsuneo Watanabe, Megumi Io, Yusuke Shintani, Junji Kamon, Masato Horikawa, Kazuya Takeuchi
-
Publication number: 20100286390Abstract: Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.Type: ApplicationFiled: October 30, 2008Publication date: November 11, 2010Inventors: Yukihiro Shigeta, Yutaka Hirokawa, Hiroshi Nagai, Kei Nagae, Tsuneo Watanabe, Megumi Io, Yusuke Shintani, Junji Kamon, Masato Horikawa, Kazuya Takeuchi